Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis

Registry will continue to advance the understanding of the clinical outcomes and management of recurrent pericarditis in partnership with the healthcare community, patients and patient advocates

HAMILTON, Bermuda, March 02, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today announced the official launch of the RESONANCE registry in pediatric and adult patients with recurrent pericarditis. Recurrent pericarditis is a painful and debilitating autoinflammatory cardiovascular disease.

“We are pleased to announce the launch of the RESONANCE registry, underscoring our commitment to partnering with the recurrent pericarditis community to better understand management and treatment in clinical practice,” said Dana R. Martin, PharmD, Senior Vice President of Medical Affairs and Patient Advocacy at Kiniksa. “RESONANCE provides an invaluable opportunity to collect uniform physician-and patient-reported data in a broad patient population. We look forward to learning more about this challenging disease in collaboration with the healthcare community and patients.”

The RESONANCE registry is a voluntary patient registry database led by physician-researchers with experience in managing patients with recurrent pericarditis. Physicians, patients, and patient advocates contributed to the finalization of the priority data to be captured in the registry, in partnership with Kiniksa. This registry intends to increase the understanding of recurrent pericarditis by encouraging the collaboration and sharing of information and expertise.

“The RESONANCE registry is an excellent next step in research to enrich the understanding of recurrent pericarditis in partnership with clinicians, patients and industry,” said Dr. Martin LeWinter, Professor of Medicine, Cardiovascular Unit at The University of Vermont, Larner College of Medicine. “A significant unmet need remains for patients suffering from pericardial disease, and I am encouraged that the planned real-world data collection in this registry may help to better inform recommendations in the management and treatment of those with recurrent pericarditis.”